LumaWave's Handheld Probe Is Chasing Tissue Oxygen at the Point of Care

The promise of photoacoustic imaging has long been confined to research labs, a powerful but bulky way to see oxygen levels deep inside tissue without a biopsy. For clinicians managing chronic wounds or monitoring fetal distress, that promise has remained just out of reach, a gap between what the science can reveal and what can fit at a patient's bedside. LumaWave, a 2025 spinout from Tulane University, is building the hardware to close it. Their bet is a handheld probe that uses pulses of light and ultrasound to map tissue oxygenation in real time, aiming to turn a complex imaging modality into a point-of-care diagnostic tool [Tulane Research, July 2026].

From Lab Bench to Bedside

The core technology is not new, but its packaging is the innovation. Photoacoustic imaging works by sending safe pulses of light into tissue; the light is absorbed by molecules like hemoglobin, generating tiny ultrasound waves that a detector can pick up. The result is a functional map of oxygen saturation, revealing hypoxic areas that standard ultrasound cannot directly show [Frontiers, 2024]. LumaWave's contribution is shrinking this system into a portable, handheld format intended for clinical settings where speed and cost matter. The initial commercial wedge is chronic wound assessment, a painful and costly condition affecting millions where current methods for measuring tissue oxygen are often slow, expensive, or impractical for high-volume clinics [bizneworleans.com, November 2025].

A Grant-Fueled Path to the Clinic

Without a disclosed priced equity round, LumaWave's trajectory has been charted through academic grants and competition prizes, a common path for deep-tech medical device startups. This non-dilutive funding has provided crucial runway for prototype development and early validation studies. The most significant vote of confidence arrived in July 2026: a $1.5 million award from the Advanced Research Projects Agency for Health (ARPA-H), specifically through its Making Obstetrics Care Smart (MOCS) program [Tulane Research, July 2026]. This grant, awarded to Tulane researchers in partnership with LumaWave, targets a formidable adjacent application: developing a sensor for directly measuring fetal tissue oxygen levels during pregnancy and labor.

The company's early milestones illustrate a focus on proving the concept and securing institutional support.

Open Season Pitch Competition | 3 | K USD
Tulane $50K Demo Day | 15 | K USD
ARPA-H MOCS Award | 1500 | K USD

The Team Translating the Science

The startup leverages a classic academic-founder structure. Carolyn L. Bayer, the CTO and co-founder, is an associate professor of biomedical engineering at Tulane whose research spans optical imaging and women's reproductive health, providing the deep technical foundation [LumaWave Inc., 2026]. Commercialization is led by CEO Vinoin “Vin” Devpaul Vincely, a recent Tulane PhD graduate and Innovation Fellow who has been the public face of the company's pitch activity [Tulane Research, July 2026]. This division of labor,Bayer steering the research pipeline and Vincely navigating commercialization,is a tested model for translating federally funded research into a venture-backed company.

The Long Road of Device Regulation

The ambition is clear, but the path to a cleared medical device is measured in years, not months. Photoacoustic imaging for diagnostic use will require rigorous clinical validation and regulatory approval from the FDA, a process that demands significant capital and time. The company's grant-focused funding, while advantageous for early development, will eventually need to be supplemented by venture capital to finance the costly clinical trials required for a 510(k) or De Novo submission. Furthermore, while the technology is versatile, focusing initially on chronic wounds and then branching into fetal monitoring represents two distinct regulatory pathways and clinical sales cycles, potentially stretching a young team's focus.

• The regulatory clock. Every day spent in development and testing is a day the standard of care persists. The company must move with urgency while not shortcutting the science.
• The capital ladder. Translating a $1.5 million grant into a tens-of-millions-dollar device trial is a classic biotech financing challenge.
• The focus question. Success in wound care does not guarantee success in obstetrics; each application requires its own clinical evidence and market education.

For patients with chronic wounds like diabetic foot ulcers or venous stasis ulcers, the current standard of care often involves visual inspection, palpation, and perhaps transcutaneous oximetry,a method that can be slow, operator-dependent, and limited in the depth of information it provides. The promise of a device like LumaWave's is a more objective, immediate read on whether underlying tissue is receiving enough oxygen to heal, potentially guiding more effective debridement and therapy choices. It is a tool aimed at a population where delayed healing can lead to severe complications, including amputation, and where better diagnostics could meaningfully improve quality of life. The next twelve months will be about moving from prototype to a product ready for the rigorous scrutiny of a clinical study, the first real test of whether this portable promise can hold up under the clinical spotlight.

Sources

1. [Tulane Research, July 2026] Tulane and LumaWave awarded $1.5 million to improve fetal monitoring during labor | https://research.tulane.edu/news/1653969/Tulane%20and%20LumaWave%20awarded%20$1.5%20million%20to%20improve%20fetal%20monitoring%20during%20labor
2. [Frontiers, 2024] Dual-modal photoacoustic and ultrasound imaging: from preclinical to clinical applications | https://www.frontiersin.org/journals/photonics/articles/10.3389/fphot.2024.1359784/full
3. [bizneworleans.com, November 2025] Idea Village Spotlights Fall 2025 Pitch Night Startups | https://bizneworleans.com/idea-village-spotlights-fall-2025-pitch-night-startups
4. [LumaWave Inc., 2026] About Us - LumaWave Team | https://www.lumawaveimaging.com/about.html
5. [bizneworleans.com, March 2026] Tulane $50K Demo Day | https://bizneworleans.com/thrivvy-leads-winners-at-tulane-50k-demo-day/
6. [innovation.tulane.edu] Open Season Pitch Competition | https://innovation.tulane.edu/tulane-students-and-faculty-compete-open-season-pitch-competition